X4 PHARMACEUTICALS INC (XFOR) Stock Price, Forecast & Analysis
USA - NASDAQ:XFOR - US98420X2027 - Common Stock
XFOR Key Statistics, Chart & Performance
The current stock price of XFOR is 3.71 USD. In the past month the price increased by 20.06%. In the past year, price decreased by -79.97%.
XFOR Latest News, Press Relases and Analysis
XFOR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About XFOR
Company Profile
X4 Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. The company is headquartered in Boston, Massachusetts and currently employs 143 full-time employees. The company went IPO on 2017-11-16. The firm is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. The company has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). The company has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
Company Info
X4 PHARMACEUTICALS INC
61 North Beacon Street, 4th Floor
Boston MASSACHUSETTS 02134 US
CEO: Paula Ragan
Employees: 143
Phone: 18575298300
X4 PHARMACEUTICALS INC / XFOR FAQ
What does X4 PHARMACEUTICALS INC do?
X4 Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. The company is headquartered in Boston, Massachusetts and currently employs 143 full-time employees. The company went IPO on 2017-11-16. The firm is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. The company has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). The company has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
What is the stock price of X4 PHARMACEUTICALS INC today?
The current stock price of XFOR is 3.71 USD. The price increased by 5.85% in the last trading session.
Does XFOR stock pay dividends?
XFOR does not pay a dividend.
How is the ChartMill rating for X4 PHARMACEUTICALS INC?
XFOR has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about X4 PHARMACEUTICALS INC (XFOR) stock?
11 analysts have analysed XFOR and the average price target is 8.87 USD. This implies a price increase of 139.19% is expected in the next year compared to the current price of 3.71.
Is X4 PHARMACEUTICALS INC (XFOR) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on XFOR.
Can you provide the upcoming earnings date for X4 PHARMACEUTICALS INC?
X4 PHARMACEUTICALS INC (XFOR) will report earnings on 2026-03-23, after the market close.
XFOR Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to XFOR. When comparing the yearly performance of all stocks, XFOR is one of the better performing stocks in the market, outperforming 89.93% of all stocks.
XFOR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to XFOR. XFOR has a bad profitability rating. Also its financial health evaluation is rather negative.
XFOR Financial Highlights
Over the last trailing twelve months XFOR reported a non-GAAP Earnings per Share(EPS) of -10.12. The EPS increased by 44.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -96.96% | ||
| ROE | -2568.02% | ||
| Debt/Equity | 19.1 |
XFOR Forecast & Estimates
11 analysts have analysed XFOR and the average price target is 8.87 USD. This implies a price increase of 139.19% is expected in the next year compared to the current price of 3.71.
For the next year, analysts expect an EPS growth of 82.32% and a revenue growth 1511.73% for XFOR